Teva Pharmaceutical Industries Limited (NYSE:TEVA) PT Raised to $13.00 at Royal Bank Of Canada

Teva Pharmaceutical Industries Limited (NYSE:TEVA) had its target price upped by Royal Bank Of Canada from $8.00 to $13.00 in a research report report published on Sunday, November 5th. They currently have an underperform rating on the stock.

Several other analysts have also recently commented on TEVA. BidaskClub cut shares of Teva Pharmaceutical Industries Limited from a buy rating to a hold rating in a research note on Tuesday, July 11th. Vetr raised shares of Teva Pharmaceutical Industries Limited from a hold rating to a buy rating and set a $32.27 target price for the company in a research note on Tuesday, July 11th. Maxim Group reiterated a hold rating and issued a $35.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, July 13th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a sell rating to a hold rating in a report on Monday, July 17th. Finally, Oppenheimer Holdings, Inc. reiterated an outperform rating and issued a $41.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Tuesday, July 18th. Seven investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Teva Pharmaceutical Industries Limited presently has a consensus rating of Hold and a consensus target price of $21.88.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up $0.22 during mid-day trading on Friday, reaching $13.70. 15,935,600 shares of the company’s stock traded hands, compared to its average volume of 15,439,824. The stock has a market cap of $13,695.68, a PE ratio of 3.11 and a beta of 0.52. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries Limited has a 12-month low of $10.85 and a 12-month high of $38.49.

WARNING: This piece was posted by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/royal-bank-of-canada-boosts-teva-pharmaceutical-industries-limited-teva-price-target-to-13-00/1760251.html.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a dividend of $0.085 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 annualized dividend and a dividend yield of 2.48%. Teva Pharmaceutical Industries Limited’s payout ratio is -15.80%.

Several large investors have recently bought and sold shares of the stock. San Francisco Sentry Investment Group CA acquired a new position in Teva Pharmaceutical Industries Limited in the 2nd quarter worth $106,000. Kistler Tiffany Companies LLC lifted its holdings in Teva Pharmaceutical Industries Limited by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares in the last quarter. Bronfman E.L. Rothschild L.P. lifted its holdings in Teva Pharmaceutical Industries Limited by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after buying an additional 94 shares in the last quarter. Cutler Capital Management LLC acquired a new position in Teva Pharmaceutical Industries Limited in the 2nd quarter worth $133,000. Finally, Shelter Mutual Insurance Co acquired a new position in Teva Pharmaceutical Industries Limited in the 2nd quarter worth $133,000. Institutional investors and hedge funds own 52.29% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.